Defendant
9 cases as defendant.
Lotus Pharmaceutical Co., Ltd. (Chinese: 美時化學製藥股份有限公司; "Lotus") is a publicly listed specialty and generic pharmaceutical company headquartered at 17F, No. 277 Song Ren Road, Xinyi District, Taipei City, Taiwan. Founded in 1966, it trades on the Taiwan Stock Exchange under ticker 1795 (listing date 2019-12-16). It is majority-owned by the Alvogen Group, which invested via private placement in 2014; Lotus in turn completed the acquisition of New Alvogen Group Holdings (Alvogen) in December 2025. Reported headcount is roughly 1,100–1,400 globally depending on source. FY2025 consolidated revenue was NT$20,509 million (~US$650M) with basic EPS of NT$18.14; 1H2026 revenue was NT$17,453 million following Alvogen consolidation.
Lotus develops, manufactures, in-licenses and commercializes medicines, with a portfolio of 250+ commercial products sold across 90+ markets. Core therapeutic areas include oncology and immunology (including lenalidomide, gefitinib, vinorelbine softgel capsules, and lurbinectedin/Zepzelca in Taiwan), CNS, cardiovascular, women's health and anti-obesity products, primarily in tablet and hard/softgel capsule form. It also provides contract manufacturing and contract research services. It operates manufacturing sites in Taiwan, the United States and South Korea, with R&D hubs in India and the United States, and states it runs a Taiwan facility approved by the US FDA, EU EMA and Japan PMDA.
Patent-litigation posture: Lotus appears in the database exclusively as a defendant (0 plaintiff cases, 4 defendant cases). That profile is consistent with an operating company defending ANDA/Hatch-Waxman challenges brought by brand manufacturers, not a patent assertion entity.
Notable cases: All four tracked matters are Celgene Corporation suits filed against Lotus in the U.S. District Court for the District of New Jersey — two dated 2017-09-06 (one before Judge Wigenton) and one dated 2018-07-10, with a fourth undated. The D.N.J. venue and Celgene counterparty align with lenalidomide (Revlimid) generic-entry litigation. The merits of those cases are not assessed here.
Celgene obtained a consent judgment against Lotus and Alvogen in a REVLIMID ANDA case. The Mar. 29, 2019 judgment enjoined defendants from marketing ANDA No. 210480 until expiration of the patents-in-suit, which expressly included U.S. 7,977,357, and dismissed all claims with prejudice under a confidential settlement license.
Celgene sued Lotus and Alvogen over ANDA No. 210480, asserting the '357, '219, and '598 patents. Markman hearings were canceled in 2019, and the docket reflects a judgment/injunction barring marketing. The case is the only '598 case indexed in the Stanford NPE Database and ended in consent judgment/injunction.
Patent infringement action listed for U.S. Patent No. 7,968,569. The related Lotus/Alvogen dispute was resolved by a 2019 settlement; Lotus/Alvogen also filed IPR2018-01714.
16-count complaint with the '740 patent among patents-in-suit; motion for judgment on the pleadings on REMS patents denied without prejudice Dec 14, 2018. Later settled March 30, 2019, with Lotus/Alvogen licensed to sell a limited-volume generic after March 2022.
Celgene sued Lotus and Alvogen in D.N.J. asserting a portfolio including US 8,626,531. The court bifurcated and stayed claims as to several patents, and a consent judgment/injunction was entered; the case terminated Sept. 5, 2019.
Celgene action against Lotus and Alvogen over lenalidomide ANDA No. 210480. The narrative states the '018 patent was not listed among the patents challenged; the Rule 12(c) challenge involved the REMS patents '720, '977, '784, '886 and '531. The motion for judgment on the pleadings was denied without prejudice on December 14, 2018.
Celgene sued Lotus and Alvogen, asserting the '717 patent among 16 patents. A consent judgment/injunction was entered on March 29, 2019, enjoining Lotus/Alvogen until expiration of the patents-in-suit, including the '717 patent.
Celgene sued Lotus Pharmaceutical and Alvogen Pine Brook for ANDA patent infringement in D.N.J. Consent judgment entered 2019-03-29 named 8,648,095 among patents-in-suit, dismissed with prejudice and enjoined Lotus ANDA No. 210480.
Celgene lenalidomide ANDA suit against Lotus and Alvogen; the '517 patent was expressly named among the patents-in-suit. A consent judgment entered March 29, 2019, included an injunction and dismissal with prejudice, with settlement allowing generic lenalidomide launch after March 2022 under volume limits.